New devices address infusion delivery variability and expand the ICU Medical IV Performance Platform. Unlike traditional pumps that rely on specific setups and conditions for accurate delivery, ...

DUBLIN--(BUSINESS WIRE)--The "Infusion Pumps and Devices: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. Infusion pumps are widely used in hospitals, ...

On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830, an investigational apomorphine infusion device under FDA review for the continuous treatment of motor ...

Patients should receive training on the proper use of the delivery device prior to starting treatment. The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ...

The global elastomeric infusion pumps growth is driven by rising demand for home-based care, ambulatory treatment, and ...

Intravenous infusion systems are a cornerstone of modern clinical care, ensuring that fluids and medications are administered at precise rates to meet patient needs. These systems are integral to a ...

A Prescription Drug User Fee Act target date of February 1, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) ...

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) said that the U.S. Food and Drug Administration has acknowledged the resubmission of the new drug application or NDA for its SPN-830, an apomorphine ...

Hyderabad, India, March 11, 2017 (GLOBE NEWSWIRE) -- The report “Infusion Therapy Devices Market: By Type(Infusion Method, Operation Type, Infusion Type) By Types of Infusion Pumps (Large Volume ...

LONDON, Sept 1 (Reuters) - Privately held company CeQur, which is developing the world's first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding ...

Supernus Pharmaceuticals (NASDAQ:SUPN) shares dipped ~11% premarket on Monday after the U.S. drug regulator rejected its experimental apomorphine infusion device for the continuous treatment of motor ...